Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma

References

• Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.
   PubMed Web of Science ®Google Scholar
• Ohishi H, Yoshimura H, Uchida H, et al. Transcatheter arterial emobolization using iodized oil (lipiodol) mixed with an anticancer drug the treatment for hepatocellular carcinoma. Cancer Chemother Pharmacol. 1989;23(S1):S33–S6.
   PubMedGoogle Scholar
• Uchida H, Ohishi H, Matsuo N, et al. Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1990;13(3):140–145.
   PubMed Web of Science ®Google Scholar
• Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365–376.
   PubMed Web of Science ®Google Scholar
• Satake M, Uchida H, Arai Y, et al. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol. 2008;31(4):756–761.
   PubMed Web of Science ®Google Scholar
• Takaki S, Sakaguchi H, Anai H, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(3):544–554.
   PubMed Web of Science ®Google Scholar
• Miyayama S, Yamashiro M, Okuda M, et al. Chemoembolization for the treatment of large hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(8):1226–1234.
   PubMed Web of Science ®Google Scholar
• Chung JW, Park JH, Im JG, et al. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1993;187(3):689–693.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Monzawa S, Nagano H, et al. Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2007;30(3):508–511.
   PubMed Web of Science ®Google Scholar
• Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, third English edition. Kanehara, Tokyo; 2010.
   Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(03):329–338.
   PubMedGoogle Scholar
• Nanashima A, Taura N, Abo T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci. 2011;56(10):3086–3100.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):052–060.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE). [cited 2011 Jun 14]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm..
   Google Scholar
• Ikai I, Kudo M, Arii S, et al. The Liver Cancer Study Group of Japan. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2010;40(11):1043–1059.
   Web of Science ®Google Scholar
• Zhu SL, Chen J, Li H, et al. Efficacy of hepatic resection for huge (≥10 cm) hepatocellular carcinoma: good prognosis associated with the uninodular subtype. Int J Clin Exp Med. 2015;8(11):20581–20588.
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee YJ, Kim KH, et al. Long-term outcome after resection of huge hepatocellular carcinoma ≥10 cm: single-institution experience with 471 patients. World J Surg. 2015;39(10):2519–2528.
   PubMed Web of Science ®Google Scholar
• Ariizumi SI, Kotera Y, Takahashi Y, et al. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol. 2013;107(4):408–413.
   PubMed Web of Science ®Google Scholar
• Choi GH, Han DH, Kim DH, et al. Outcome after curative resection for a huge (≥10cm) heptocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg. 2009;198(5):693–701.
   PubMed Web of Science ®Google Scholar
• Shah SA, Wei AC, Cleary SP, et al. Prognosis and results after resection of very large (>10 cm) hepatocellular carcinoma. J Gastrointest Surg. 2007;11(5):589–595.
   PubMed Web of Science ®Google Scholar
• Poon RT, Ngan H, Lo CM, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol. 2000;73(2):109–114.
   PubMed Web of Science ®Google Scholar
• Min YW, Lee JH, Gwak GY, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29(5):1043–1048.
   PubMed Web of Science ®Google Scholar
• Takayasu K, Arii S, Ikai I, et al. Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Roentgenol. 2010;194(3):830–837.
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, On Behalf of the PRECISION V Investigators, et al. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.
   PubMed Web of Science ®Google Scholar